CBC Group and Mubadala Acquire UCB's Mature China Neurology & Allergy Portfolio to Create NeuroGen Pharma

UCB to Acquire Neurona Therapeutics for up to $1.15 Billion to Advance Epilepsy Cell Therapy

April 21, 2026

Healthcare Services

UCB announced a definitive agreement to acquire Neurona Therapeutics in a deal valued at up to $1.15 billion, including $650 million upfront and up to $500 million in potential milestone payments. The acquisition is intended to strengthen UCB’s epilepsy portfolio and expand it into regenerative medicine via Neurona’s lead cell therapy, NRTX-1001.

Neurocrine Biosciences to Acquire Celeno Therapeutics

April 7, 2026

Healthcare Services

Neurocrine Biosciences entered into a definitive all-cash agreement to acquire Celeno Therapeutics for approximately $2.9 billion. The deal is structured as a tender offer and is expected to close within ~90 days, subject to Hart-Scott-Rodino antitrust clearance and a majority of Celeno shares being tendered.

Clario Acquires NeuroRx

March 19, 2025

Healthcare Services

Clario has acquired NeuroRx, a Montreal-based imaging analysis provider specializing in neuroimaging for clinical trials, to strengthen Clario's neuroscience capabilities. NeuroRx founder Douglas Arnold will join Clario as Senior Scientific Advisor as the company integrates NeuroRx's imaging expertise to support drug development in CNS indications.

Pharmanovia Acquires Global CNS Portfolio from Sanofi

September 18, 2023

Pharmaceuticals

Pharmanovia, a Triton Fund V portfolio company, has acquired an 11‑brand global central nervous system (CNS) portfolio from Sanofi, including Frisium (clobazam) and Gardenal (phenobarbital). The asset package, available in 60+ markets, expands Pharmanovia's neurology franchise and commercial footprint across markets such as Brazil, South Africa, France and Italy in a divestiture from Sanofi.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

UCB to Acquire Zogenix for up to $1.9B

January 19, 2022

Pharmaceuticals

UCB (Euronext: UCB) has agreed to acquire Zogenix, Inc. (NASDAQ: ZGNX) in a cash tender offer valuing the deal at up to approximately US$1.9 billion, consisting of US$26.00 per share in cash plus a contingent value right of up to US$2.00 per share tied to regulatory milestones. The acquisition adds Zogenix's FINTEPLA (fenfluramine) — an approved treatment for seizures associated with Dravet syndrome and under review for Lennox-Gastaut syndrome — to UCB's neurology and rare disease portfolio and is expected to expand UCB's epilepsy pipeline and global commercial reach.